I keep thinking of the Agent Orange settlement as an example of a certain type of victory that doesn’t seem like one. Seven chemical corporations, including Dow and Monsanto, agreed to pay $180 million to settle the class-action case brought by Vietnam veterans exposed to the herbicide on May 7, 1984, just hours before a jury was scheduled to be chosen in a federal courtroom in Brooklyn. It was a landmark on paper. Reached against some of America’s most prominent firms, it was the biggest settlement of its kind at the time. In reality, it was the start of a battle that would persist for many of the soldiers who had brought the toxin home with them.
In 1984, the sum sounded huge, but when you divided it among the people it was intended to assist, it practically vanished. There were over 2.4 million American service troops in Vietnam. Veterans with total disabilities and their surviving families received an average of $12,000 or less per individual from the fund, which ultimately distributed around $197 million with accrued interest. Twelve thousand dollars for a lifetime of illness, including diabetes, cancer, brain damage, and birth problems in children. Additionally, there was a nasty catch in the arrangement: if a veteran accepted the payment, they would no longer be entitled for state benefits, which were worth far more. After doing the math, a few males declined the money. They are not to fault.
The fact that the firms never acknowledged anything was what hurt the most, and it still does when you read the old reports. There was no admission of responsibility or admission that anyone had been damaged by the dioxin in Agent Orange as part of the settlement. With their denials intact, the businesses signed a check and left. The veterans received insufficient compensation and never received an apology. That deal has an almost classic quality: the powerful institution resolves its exposure with a payment that is manageable and a clause that shields it from ever having to say “sorry.” It is a recurring theme in American mass tort history, and the victims are rarely satisfied.
After 1984, the legal drama continued for years. Appeals accumulated. It wasn’t until 1989 that the Supreme Court upheld the agreement, and the settlement fund didn’t officially close until 1997, thirteen years after the agreement was reached, by which time many of the initial claimants had passed away or were near death. In 1984, the fund closed for a veteran in his forties who was nearing his sixties and still battling a disease that its perpetrators had never acknowledged. The slowness wasn’t accidental. Time is a sort of defense in this kind of case, and the men who needed assistance the most quickly were the ones who could not wait.
Congress, not the courts, was the real turning point since the private settlement was so insufficient to cover the true expenses. The statute that truly improved the lives of veterans was the Agent Orange Act of 1991, which accomplished this through a seemingly straightforward system known as presumptive benefits. The measure eliminated the harsh burden of proving individual exposure decades after the fact, frequently with data that were no longer available, by requiring the government to assume that any veteran who served in Vietnam during the war had been exposed to the herbicides. The VA now assumes the link if you served there and developed a specified condition. More than the $180 million, it was that change that provided long-term care to those in need.
Since then, the framework has continued to grow, and it’s important to recognize how much of this growth is due to ongoing litigation. The Nehmer court orders, which resulted from a different long-running dispute, compel the VA to implement new presumed conditions retroactively, allowing veterans whose claims were refused years ago to have them reexamined when science advances. Bladder cancer, ischemic heart disease, Parkinson’s disease, type 2 diabetes, multiple myeloma, and a lengthy list of other presumed diseases linked to Agent Orange are now recognized by the VA. In 1984, science continued to uncover more harm than anyone could comprehend, and the legislative and legal framework continued to expand, albeit slowly and inadequately.
The PACT Act, which was passed in August 2022, is the most current chapter and the biggest increase in toxic-exposure benefits in over thirty years. MGUS, a blood disorder, and hypertension were listed as new Agent Orange putative disorders. The latter will go into full force on October 1, 2026, this year. It acknowledged that the herbicides had been used and stored far more broadly than the original framework acknowledged, extending the recognized exposure areas well beyond Vietnam to include Thailand, Laos, Cambodia, Guam, American Samoa, and Johnston Atoll.
Notably, since the VA began processing PACT Act petitions, hypertension has emerged as the most frequently reported new condition. This indicates the number of elderly veterans who have been dealing with an ailment that the government has only recently consented to link to their service.
Looking back at this, it’s difficult not to feel two things at once. This nation has made real progress, however slowly and reluctantly, in developing a system that now assumes harm rather than requiring dying men to prove it. And there’s the lengthy shadow of how it all began: a settlement that compensated the injured a meager sum, allowed the makers to get away with it, and forced the actual battle into a legislative path that took decades to produce results.
Even now, there are ongoing litigation against Monsanto’s parent firm, Bayer, alleging that the businesses supplied the military despite knowing about the risks posed by dioxin. In other words, nothing was resolved by the previous settlement. It simply signaled the point at which the courts gave up and the slower, more drawn-out process of formulating policy started.
